Captrust Financial Advisors Regenxbio Inc. Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$19.35 - $35.04 $6,830 - $12,369	-353 Reduced 36.77%	607 $15,000
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $20,828 - $29,026	846 Added 742.11%	960 $32,000
Q4 2021 Feb 14, 2022	BUY	$30.19 - $40.28 $422 - $563	14 Added 14.0%	114 $4,000
Q3 2021 Nov 16, 2021	BUY	$29.09 - $45.68 $610 - $959	21 Added 26.58%	100 $4,000
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $421 - $526	-13 Reduced 14.13%	79 $3,000
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $1,243 - $1,848	37 Added 67.27%	92 $3,000
Q4 2020 Feb 16, 2021	BUY	$26.52 - $49.35 $663 - $1,233	25 Added 83.33%	55 $2,000
Q3 2020 Nov 17, 2020	BUY	$27.01 - $40.26 $810 - $1,207	30 New	30 $1,000

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $420M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.